Yahoo · Feb 27, 2026
Best Growth Stocks to Buy for February 27th
DVA, ALL, and PAX it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2026.
NYSE · DVA
DaVita Inc.
Healthcare · Medical - Care Facilities
$176.14
Up+$0.13 (+0.07%)
Updated Sep 2, 2026, 11:31 AM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 8.49B
- P/E ratio
- 11.23
- Dividend yield
- 0.00%
- 52-week range
- $101.00 – $247.49
- Volume
- 672.63K
- Avg. volume
- 887.38K
Price performance
DVA price history
1M range · 21 trading sessions · Daily adjusted prices
DVA closed at $176.14 after 21 trading sessions, down 22.74% for the selected period.
- Last close
- $176.14
- Period change
- -22.74%
- Period low
- $173.82
- Period high
- $227.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $176.32 | $179.0425 | $175.47 | $176.14 | 672.63K |
| Aug 31, 2026 | $179.74 | $180.355 | $175.705 | $176.01 | 573.91K |
| Aug 28, 2026 | $180.00 | $182.53 | $178.8004 | $180.68 | 461.8K |
| Aug 27, 2026 | $178.00 | $179.78 | $175.90 | $178.88 | 489.93K |
| Aug 26, 2026 | $173.37 | $182.255 | $173.37 | $180.05 | 528.81K |
| Aug 25, 2026 | $175.605 | $179.34 | $175.295 | $177.80 | 578.49K |
| Aug 24, 2026 | $174.03 | $177.17 | $171.40 | $176.50 | 1.11M |
| Aug 21, 2026 | $175.25 | $176.19 | $173.7407 | $173.82 | 633.64K |
| Aug 20, 2026 | $176.69 | $177.535 | $175.13 | $175.24 | 483.44K |
| Aug 19, 2026 | $178.77 | $180.24 | $176.96 | $177.27 | 413.98K |
| Aug 18, 2026 | $178.13 | $179.8299 | $176.90 | $177.91 | 489.53K |
| Aug 17, 2026 | $177.97 | $180.00 | $176.20 | $176.70 | 499.95K |
| Aug 14, 2026 | $179.00 | $182.69 | $178.92 | $180.06 | 506.57K |
| Aug 13, 2026 | $182.88 | $183.57 | $178.92 | $179.17 | 655.54K |
| Aug 12, 2026 | $178.00 | $183.275 | $176.85 | $181.50 | 1.21M |
| Aug 11, 2026 | $183.18 | $186.96 | $177.91 | $178.34 | 1.11M |
| Aug 10, 2026 | $182.33 | $183.945 | $180.55 | $183.69 | 786.71K |
| Aug 7, 2026 | $181.94 | $183.87 | $176.585 | $183.77 | 1.25M |
| Aug 6, 2026 | $186.01 | $188.2381 | $178.90 | $180.67 | 1.82M |
| Aug 5, 2026 | $205.25 | $208.53 | $183.62 | $188.69 | 3.81M |
| Aug 4, 2026 | $228.00 | $234.26 | $222.80 | $227.99 | 2.61M |
Latest DVA news
The latest Smart Investors Daily articles mentioning DVA.
Stock researchCompany · Overview
DVA research
Overview
Company profile and research snapshot.
Company profile
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $141.50
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | Truist Securities | Hold | — |
| Aug 5, 2026 | Barclays | Equal-Weight | — |
| Jul 14, 2026 | Truist Securities | Hold | — |
| Jul 10, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 27, 2026
DaVita’s 20-Year Fortune Streak And What It Signals For Investors
DaVita (NYSE:DVA) has been named to Fortune's World's Most Admired Companies list for the 20th consecutive year. The company ranked third in its category, with recognition tied to culture, clinical focus, and social responsibility. This milestone reflects long running external recognition of DaVita's employer brand and approach to patient care. For investors watching NYSE:DVA, this recognition arrives with the stock at a share price of $152.54 and multi year returns of 88.4% over 3 years...
Yahoo · Feb 26, 2026
DaVita Celebrates 20 Years on Fortune's List of World's Most Admired Companies
Two decades of recognition underscore leadership in clinical innovation, employer strategy NORTHAMPTON, MA / ACCESS Newswire / February 26, 2026 / DaVita, a leading provider of comprehensive kidney care, has been named to Fortune's World's Most Admired ...
Yahoo · Feb 24, 2026
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 11:50 am EST.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
